GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2009

Takeda to Acquire IDM Pharma for $66.7M

  • Takeda Pharmaceutical Company  entered into an agreement to acquire IDM Pharma  for $2.64 per share in an all-cash tender offer followed by a merger. The company has 25.27 million shares outstanding as of today, putting the value of the deal at $66.7 million.

    Millennium: The Takeda Oncology Company, Takeda's business unit responsible for global oncology strategy and development, will have global development responsibility for Mepact®, IDM Pharma's primary asset. Takeda Pharmaceuticals Europe will be responsible for commercializing Mepact in Europe.

    IDM Pharma received European marketing approval for Mepact (mifamurtide), a therapy indicated for the treatment of nonmetastatic osteosarcoma following surgical removal of the tumor in children, adolescents, and young adults. The European Commission formally granted a centralized marketing authorization for Mepact earlier this year.


    Related News

    Takeda to Scoop Up Millennium for $8.8B (Apr. 10, 2008)

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »